Climb Bio, Inc. (CLYM) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -719.1%, revenue growth -14.6% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $8.32M |
| Revenue (TTM) | $0.0B |
| Net Margin | -719.1% |
| Return on Equity | -24.1% |
| Operating Margin (TTM) | -895.4% |
| Current Ratio | 31.45 |
| Revenue Growth (YoY) | -14.6% |
| EPS Growth (YoY) | 38.5% |
| FCF Growth (YoY) | -3.7% |
| Price / Book | 3.41 |
| Price / Sales | 112.97 |
| FCF Yield | -6.7% |
| Altman Z-Score | 53.09 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
CLYM overview · CLYM earnings · CLYM KPIs · CLYM documents · CLYM ownership · CLYM peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.